Trial
NCT00353457
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
Bristol-Myers Squibb; Roche Pharma AG
Condition
Rectal Cancer
Intervention
Capecitabine, Oxaliplatin and Cetuximab
Why stopped
new studies were finding that Erbitux was not beneficial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-09